Spyre Therapeutics, Inc.SYRENASDAQ
Loading
Year-over-year operating income growth rate
Latest
-0.50%
↑ 98% vs avg
Percentile
P64
Within normal range
Streak
1 qtr
Consecutive growthAccelerating
Average
-29.00%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | -0.50% |
| Q3 2025 | -35.66% |
| Q2 2025 | 21.71% |
| Q1 2025 | 12.55% |
| Q4 2024 | -10.58% |
| Q3 2024 | -25.47% |
| Q2 2024 | 7.59% |
| Q1 2024 | -4.05% |
| Q4 2023 | -150.39% |
| Q3 2023 | 88.49% |
| Q2 2023 | -746.78% |
| Q1 2023 | 1.86% |
| Q4 2022 | -2.17% |
| Q3 2022 | 16.36% |
| Q2 2022 | 8.26% |
| Q1 2022 | -19.56% |
| Q4 2021 | -0.73% |
| Q3 2021 | -202.65% |
| Q2 2021 | 63.18% |
| Q1 2021 | 20.05% |
| Q4 2020 | -25.67% |
| Q3 2020 | 15.94% |
| Q2 2020 | -13.34% |
| Q1 2020 | 13.18% |
| Q4 2019 | 1.07% |
| Q3 2019 | -18.92% |
| Q2 2019 | -5.47% |
| Q1 2019 | -15.37% |
| Q4 2018 | -25.01% |
| Q3 2018 | -26.61% |
| Q2 2018 | -17.28% |
| Q1 2018 | -24.43% |
| Q4 2017 | 17.15% |
| Q3 2017 | -19.02% |
| Q2 2017 | -6.14% |
| Q1 2017 | -14.22% |
| Q4 2016 | 12.03% |
| Q3 2016 | -14.67% |
| Q2 2016 | -20.32% |
| Q1 2016 | -14.26% |